Purchasing price of Gleevec in India 13621079267 Purchasing Gleevec in India

'',, 'r '[Commercial name] Gleevec
, '',, 'r '[Common name] Imatinib mesylate capsules< ..
, '', , 'r '【English name】
, '',, 'r '【Chinese Pinyin】
, '',, 'r '【Main ingredient】Imatinib mesylate
, '',, 'r '[Characteristics] Gleevec is a capsule, and the content is white to off-white powder.
, '',, 'r '[
Indications, '',, 'r '] For the treatment of chronic myelogenous leukemia () blast phase, accelerated phase or after failure of interferon therapy patients in chronic phase. For the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumors
, '',, 'r '().
, '',, 'r '[
Usage and Dosage, '',, 'r ']
, '',, 'r ' Treatment should focus on chronic myeloid Doctors who have experience in the treatment of leukemia. The recommended dose of imatinib mesylate for patients in the blast phase and accelerated phase is /day, and for patients in the chronic phase who have failed interferon treatment, it is /day. Both are taken orally once a day. It is advisable to take the medicine with a meal and drink it once a day. A large glass of water and should be continued for as long as it is effective. If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from /day to /day, or from /day to /day (oral, divided dose) under the following circumstances: disease progression, after at least one month of treatment A satisfactory hematological response cannot be obtained, and the hematological response that has been achieved disappears again.
, '',, 'r '[Pharmacology and Toxicology]
, '',, 'r ' Mechanism of action/pharmacodynamic properties: Imatinib can act on the cellular level both in vivo and in vitro Inhibiting b tyrosine kinase can selectively inhibit the proliferation and induce apoptosis of b-positive cell line cells, Philadelphia chromosome-positive (+) chronic myelogenous leukemia () and fresh cells of acute lymphoblastic leukemia patients. In addition, imatinib also inhibits the tyrosine kinases of the platelet-derived growth factor (PDGF) receptor and stem cell factor (PDGF)-receptor, thereby inhibiting cell behaviors mediated by and stem cell factor. Gastrointestinal stromal tumors
, '',, 'r '() cells express active mutations, and in vitro experiments show that imatinib inhibits cell proliferation and induces apoptosis. Preclinical and clinical data suggest that some patients may develop resistance through different mechanisms. The clinical study of chronic myelogenous leukemia (see table) conducted three groups of open, Uncontrolled phase-1 clinical study. In a large, open-label, controlled phase 1 clinical trial, patients had newly diagnosed Philadelphia chromosome-positive chronic leukemia (Philadelphia+). Treatment of children and adolescents was conducted in two phase studies. Among clinical study cases, the age of patients ranged from % to % & years, to % & years.
, '',, 'r ' Newly diagnosed chronic phase: A phase 1 clinical trial comparing imatinib mesylate mg/day vs. &-The efficacy of interferon () million//day + cytarabine () mg//day (day/month). % of patients had received hydroxyurea before taking the trial drug, and during the first months of the trial, % of patients taking imatinib mesylate and % of patients taking - also continued to take hydroxyurea (means: and sky). At the interim analysis 6 months later, the complete hematologic response (R) was .% and .% in the imatinib mesylate group and -.%, the major cytogenetic response was .% and .%, and the complete cytogenetic response (R) was .% and .%, respectively. The chemical reactions are .% and .%. The validated -BR questionnaire was used to evaluate the quality of life. The scores of all aspects of the imatinib mesylate group were higher than those of the -group. The quality of life data showed that patients receiving imatinib mesylate treatment were able to maintain a happy mood.
, '',, 'r ' - Chronic phase patients who have failed interferon therapy: (eg, starting dose mg once daily) % of patients achieved a major cytogenetic response, % achieved a complete response ,% achieved a complete hematological response. Accelerated phase: (cases, % of patients had received other treatments during the accelerated phase, % of patients received imatinib mesylate mg, once daily, % of patients received mg, once daily). Results: % of patients achieved a definite hematological response, % of patients achieved a complete hematological response, % of patients achieved a corresponding cytogenetic response, % of patients achieved a major cytogenetic response (i.e., the number of dividing Philadelphia chromosome-positive cells was reduced to <%) % of patients achieved Complete cytogenetic remission. Analysis using hematological response as the primary endpoint found no significant differences between the mg and mg dose groups, but the improvement in cytogenetic response was more pronounced and lasted longer in the mg dose group. In this study, the time required for disease progression was significantly different among the milligram dose groups.
, '',, 'r ' Blast phase (myeloid blast crisis): (cases, cases [%] have received chemotherapy after entering the accelerated phase or blast phase, and other cases [%] have received chemotherapy before had not received chemotherapy. Examples started treatment at a dose of 1 mg once daily). Statistics were based on different complete hematological responses as the main efficacy. % achieved a positive hematological response (% of patients who had not received treatment, % of treated patients), and corresponding cytogenetic responses were observed in % of patients. The median survival times for untreated and treated patients were . and . months, respectively.
, '',, 'r ' Patients who failed interferon therapy (chronic phase): (eg, starting dose, once daily) % of patients achieved a corresponding cytogenetic response, % achieved complete remission, % achieved a complete hematologic response.